symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
LRMR,3.14,0.170625,208967,135891350,0,2.58-6.85,0.06,"Larimar Therapeutics, Inc.",USD,0001374690,US5171251003,517125100,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.larimartx.com,"Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.",Dr. Carole S. Ben-Maimon M.D.,Healthcare,US,26,844 511 9056,Three Bala Plaza East,Bala Cynwyd,PA,19004,,0,https://financialmodelingprep.com/image-stock/LRMR.png,2014-06-19,False,False,True,False,False
